Modulation of the gut-liver axis by oxymatrine alleviates metabolic dysfunction-associated steatotic liver disease

Figure 6 Oxymatrine reverses hepatic metabolite changes in metabolic dysfunction-associated steatotic liver disease rats. A: Principal component analysis scores (positive/negative modes); B: Orthogonal partial least squares discriminant analysis score plots (positive and negative ion modes); C: Orthogonal partial least squares discriminant analysis permutation tests: Both ion modes; D: Top 150 hepatic metabolites: Heatmap visualization; E: The levels of adrenic acid, luteolin, oleoylethanolamide and pomiferin in the hepatic metabolites among the three groups, n = 6; F: Enrichment analysis of differential hepatic metabolites in Kyoto Encyclopedia of Genes and Genomes pathways (control, model, oxymatrine). ^aP < 0.05, ^bP < 0.01 and ^cP < 0.001. Statistical analysis was conducted using one-way analysis of variance with Tukey’s post hoc test, and results are presented as mean ± SD. Group A: Control; Group B: Model; Group C: Oxymatrine; NS: Not significant.